Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004996844 | SCV005582792 | uncertain significance | Cardiovascular phenotype | 2024-07-02 | criteria provided, single submitter | clinical testing | The c.500A>G (p.K167R) alteration is located in exon 5 (coding exon 3) of the FHL1 gene. This alteration results from a A to G substitution at nucleotide position 500, causing the lysine (K) at amino acid position 167 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005110277 | SCV005814932 | uncertain significance | X-linked myopathy with postural muscle atrophy | 2024-09-02 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 167 of the FHL1 protein (p.Lys167Arg). This variant is present in population databases (rs778371222, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with FHL1-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |